| Authors: |
Altés A; Family Medicine, Sants Primary Care Center, Barcelona, Spain., Moreno-Pérez Ó; Department of Endocrinology and Nutrition, General University Hospital Dr. Balmis of Alicante. Institute of Health and Biomedical Research of Alicante (ISABIAL), Alicante, Spain.; Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain., Sastre-Belío M; Market Access and Healthcare Consulting, Cencora PharmaLex Spain, Barcelona, Spain., Rodríguez-Urgellés E; Market Access and Healthcare Consulting, Cencora PharmaLex Spain, Barcelona, Spain., Pérez-Alcántara F; Market Access and Healthcare Consulting, Cencora PharmaLex Spain, Barcelona, Spain., Larsen S; Novo Nordisk A/S, Copenhagen, Denmark., Martín-Lorenzo A; Department of Market Access and Public Affairs, Novo Nordisk España, Madrid, Spain. ATQL@novonordisk.com., Sandín M; Cardiology Department, General University Hospital Dr. Balmis of Alicante. Institute of Health and Biomedical Research of Alicante (ISABIAL), Alicante, Spain., Vidal J; Department of Endocrinology, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.; Endocrinology and Nutrition Department, Hospital Clinic of Barcelona, Barcelona, Spain. |
